Ian Sanne

Ian M. Sanne, MBBCH

Adjunct Associate Professor, Global Health - Boston University School of Public Health


Professor Ian Matthias Sanne is a South African born infectious diseases doctor and has been involved in HIV and TB research since qualifying as internist in 1996. Since 2003 he has led the Wits HIV Research Group Clinical Trials Unit, and from 2003- 2012 led the Adult Treatment Research Site. He currently holds the AIDS Clinical Trials Group International Vice-Chair position and is responsible for overseeing the network’s research at 25 international sites in 13 countries and assisting in the prioritization of the research agenda. The focus of his research attention is an integrated program of HIV and TB research from prospective phase I-IV clinical trials, conducted predominantly through international collaborations with the NIH, EDCTP, Global TB Alliance and the Medical Research Council of South Africa. The key focus in the ACTG collaboration is prospective research to inform diagnostic, prevention and treatment interventions to optimize the diagnosis and treatment of HIV and tuberculosis. In addition through programs of implementation sciences and monitoring evaluation data produced as part of the Right to Care PEPFAR implementation program epidemiologic and health economic evaluation of health care interventions. The overall aim is to develop evidence based health system strengthening interventions to address the public health emergencies facing the resource poor setting. At the intersection of clinical care, and clinical trial administration, Professor Sanne continues to provide expertise to the ACTG leadership from the experience gained as the founding Director and Chief Executive Officer of Right to Care.


  • University of the Witwatersrand, MBBCh Field of Study: Medicine-Surgery
  • University of the Witwatersrand, DTM&H


  • Published on 2/8/2023

    Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 Feb 08; 76(3):e580-e589. PMID: 36041016.

    Read At: PubMed
  • Published on 12/8/2022

    Mekota AM, Gillespie SH, Hoelscher M, Diacon AH, Dawson R, Churchyard G, Sanne I, Minja L, Kibiki G, Maboko L, Lakhi S, Joloba M, Alabi A, Kirenga B, McHugh TD, Grobusch MP, Boeree MJ. Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach. Acta Trop. 2023 Feb; 238:106776. PMID: 36502888.

    Read At: PubMed
  • Published on 12/1/2022

    Jassat W, Abdool Karim SS, Ozougwu L, Welch R, Mudara C, Masha M, Rousseau P, Wolmarans M, Selikow A, Govender N, Walaza S, von Gottberg A, Wolter N, Terrence Pisa P, Sanne I, Govender S, Blumberg L, Cohen C, Groome MJ. Trends in Cases, Hospitalization and Mortality Related to the Omicron BA.4/BA.5 Sub-Variants in South Africa. Clin Infect Dis. 2022 Dec 01. PMID: 36453094.

    Read At: PubMed
  • Published on 11/17/2022

    Antoniak S, Chasela CS, Freiman MJ, Stopolianska Y, Barnard T, Gandhi MM, Liulchuk M, Tsenilova Z, Viktor T, Dible J, Wose Kinge C, Akpan F, Minior T, Sigwebela N, Mohamed S, Barralon M, Marange F, Cavenaugh C, Horst CV, Antonyak S, Xulu T, Chew KW, Sanne I, Rosen S. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine. JGH Open. 2022 Dec; 6(12):894-903. PMID: 36514496.

    Read At: PubMed
  • Published on 9/23/2022

    Moyo K, Igaba N, Wose Kinge C, Chasela C, Phohole M, Grove S, Makura C, Mudau L, Taljaard D, Rech D, Ramkissoon A, Searle C, Majuba P, Sanne I. Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting. PLoS One. 2022; 17(9):e0270545. PMID: 36149904.

    Read At: PubMed
  • Published on 7/27/2022

    Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. BMC Infect Dis. 2022 Jul 27; 22(1):650. PMID: 35896987.

    Read At: PubMed
  • Published on 7/26/2022

    Maskew M, Sharpey-Schafer K, De Voux L, Crompton T, Bor J, Rennick M, Chirowodza A, Miot J, Molefi S, Onaga C, Majuba P, Sanne I, Pisa P. Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Sci Rep. 2022 Jul 26; 12(1):12715. PMID: 35882962.

    Read At: PubMed
  • Published on 6/21/2022

    Takuva S, Takalani A, Seocharan I, Yende-Zuma N, Reddy T, Engelbrecht I, Faesen M, Khuto K, Whyte C, Bailey V, Trivella V, Peter J, Opie J, Louw V, Rowji P, Jacobson B, Groenewald P, Dorrington RE, Laubscher R, Bradshaw D, Moultrie H, Fairall L, Sanne I, Gail-Bekker L, Gray G, Goga A, Garrett N. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Med. 2022 Jun; 19(6):e1004024. PMID: 35727802.

    Read At: PubMed
  • Published on 5/13/2022

    Wose Kinge C, Hanekom S, Lupton-Smith A, Akpan F, Mothibi E, Maotoe T, Lebatie F, Majuba P, Sanne I, Chasela C. Persistent Symptoms among Frontline Health Workers Post-Acute COVID-19 Infection. Int J Environ Res Public Health. 2022 May 13; 19(10). PMID: 35627472.

    Read At: PubMed
  • Published on 3/30/2022

    Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Wose Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 Jun; 29(6):474-486. PMID: 35278339.

    Read At: PubMed